Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATSGO study of prolonged adjuvant temozolomide versus stop-and-go in glioblastoma
2006-004635-30Phase 2Completed
- Sponsor
- King Albert II Cancer Institute
- Start
- Oct 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of temozolomide in glioblastoma (GBM), sponsored by King Albert II Cancer Institute. Started Oct 2007; status: completed.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2006-004635-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004635-30.